3,4-dihydro-4-oxo-2H-1-benzopyran-3-acetic acid | 112639-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,4-dihydro-4-oxo-2H-1-benzopyran-3-acetic acid
• 英文别名: 2-(4-Oxo-2,3-dihydrochromen-3-yl)acetic acid
• CAS: 112639-38-0
• 化学式: C₁₁H₁₀O₄
• 分子量: 206.198
• InChiKey: ZOPKCXNPYUFUFY-UHFFFAOYSA-N

物化性质

• 熔点：
  109-110 °C(Solv: benzene (71-43-2))
• 沸点：
  428.7±34.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-dihydro-4-oxo-2H-1-benzopyran-3-acetic acid 在 正丁基锂 、 magnesium methanolate 、 异丙胺 、 间氯过氧苯甲酸 、 氢化铝 、 mercury dichloride 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 、 二氯甲烷 、 仲丁醇 为溶剂， 反应 38.0h， 生成 4-(3,4-dihydro-cis-4-hydroxy-2H-1-benzopyran-3-yl)-1,3-benzenediol
  参考文献：
  名称：

  Ozaki, Yutaka; Mochida, Keiko; Kim, Sang-Won, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 5, p. 1790 - 1795

  摘要：

  DOI：
• 作为产物：
  描述：

  diethyl (3,4-dihydro-4-oxo-2H-1-benzopyran-3-yl)malonate 在 甲酸 、 硫酸 作用下， 以 溶剂黄146 为溶剂， 反应 10.0h， 以73.5%的产率得到3,4-dihydro-4-oxo-2H-1-benzopyran-3-acetic acid
  参考文献：
  名称：

  Ozaki, Yutaka; Mochida, Keiko; Kim, Sang-Won, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 5, p. 1790 - 1795

  摘要：

  DOI：

文献信息

• Pyridazinones and triazinones and medicinal use thereof
  申请人：——

  公开号：US20030225081A1

  公开（公告）日：2003-12-04

  The present invention provides a novel compound exhibiting an excellent inhibitory action on AMPA receptor and/or kainate receptor. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. 1 In the formula, A 1 , A 2 and A 3 are independent of each other and each represents a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may be substituted; Q represents O, S or NH; Z represents C or N; X 1 , X 2 and X 3 are independent of each other and each represents a single bond, an optionally substituted C 1-6 alkylene group, an optionally substituted C 2-6 alkenylene group, an optionally substituted C 2-6 alkynylene group, —NH—, —O—, —NHCO—, —CONH—, —SO 0-2 , etc.; R 1 and R 2 are independent of each other and each represents a hydrogen atom or an optionally substituted C 1-6 alkyl group, or R 1 and R 2 may be bound together such that CR 2 -ZR 1 forms C═C; and R 3 represents a hydrogen atom or an optionally substituted C 1-6 alkyl group etc., or may be bound to any atom in A 1 or A 3 to form, together with the atom, an optionally substituted C 5-8 hydrocarbon ring or an optionally substituted 5- to 8-membered heterocyclic ring.

  本发明提供了一种在AMPA受体和/或翘曲酸受体上表现出优异的抑制作用的新型化合物。也就是说，它提供了以下公式所代表的化合物、其盐或其水合物。在该公式中，A1、A2和A3彼此独立，每个代表一个C3-8环烷基、一个C3-8环烯基、一个5-至14-成员非芳香杂环基、一个C6-14芳香烃环基或一个5-至14-成员芳香杂环基，每个都可以被取代；Q代表O、S或NH；Z代表C或N；X1、X2和X3彼此独立，每个代表一个单键，一个可选择取代的C1-6烷基基团，一个可选择取代的C2-6烯基基团，一个可选择取代的C2-6炔基基团，—NH—、—O—、—NHCO—、—CONH—、—SO0-2等；R1和R2彼此独立，每个代表一个氢原子或一个可选择取代的C1-6烷基基团，或者R1和R2可以结合在一起，使得CR2-ZR1形成C═C；和R3代表一个氢原子或一个可选择取代的C1-6烷基基团等，或者可以与A1或A3中的任何原子结合，与该原子一起形成一个可选择取代的C5-8碳氢环或一个可选择取代的5-至8-成员杂环环。
• Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
  申请人：Nagato Satoshi

  公开号：US20060189622A1

  公开（公告）日：2006-08-24

  The present invention provides a novel compound exhibiting an excellent inhibitory action on AMPA receptor and/or kainate receptor. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. In the formula, A 1 , A 2 and A 3 are independent of each other and each represents a C 3-8 cycloalkyl group, a C 3-8 cycloalkenyl group, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may be substituted; Q represents O, S or NH; Z represents C or N; X 1 , X 2 and X 3 are independent of each other and each represents a single bond, an optionally substituted C 1-6 alkylene group, an optionally substituted C 2-6 alkenylene group, an optionally substituted C 2-6 alkynylene group, —NH—, —O—, —NHCO—, —CONH—, —SO 0-2 —, etc.; R 1 and R 2 are independent of each other and each represents a hydrogen atom or an optionally substituted C 1-6 alkyl group, or R 1 and R 2 may be bound together such that CR 2 -ZR 1 forms C═C; and R 3 represents a hydrogen atom or an optionally substituted C 1-6 alkyl group etc., or may be bound to any atom in A 1 or A 3 to form, together with the atom, an optionally substituted C 5-8 hydrocarbon ring or an optionally substituted 5- to 8-membered heterocyclic ring.

  本发明提供了一种新型化合物，它表现出对AMPA受体和/或kainate受体的优异抑制作用。即，它提供了由以下公式表示的化合物，其盐或水合物。在该公式中，A1、A2和A3相互独立，每个表示C3-8环烷基、C3-8环烯基、5-至14元非芳杂环基、C6-14芳香烃环基或5-至14元芳香杂环基，每个都可以被取代；Q表示O、S或NH；Z表示C或N；X1、X2和X3相互独立，每个表示单键、可选取代的C1-6烷基、可选取代的C2-6烯基、可选取代的C2-6炔基、—NH—、—O—、—NHCO—、—CONH—、—SO0-2—等；R1和R2相互独立，每个表示氢原子或可选取代的C1-6烷基，或者R1和R2可以结合在一起，使CR2-ZR1形成C═C；R3表示氢原子或可选取代的C1-6烷基等，或者可以与A1或A3中的任何原子结合，在一起形成可选取代的C5-8碳氢环或可选取代的5-至8元杂环。
• PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1319659A1

  公开（公告）日：2003-06-18

  The present invention provides a novel compound exhibiting an excellent inhibitory action on AMPA receptor and/or kainate receptor. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.    In the formula, A1, A2 and A3 are independent of each other and each represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a 5- to 14-membered non-aromatic heterocyclic group, a C6-14 aromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may be substituted; Q represents O, S or NH; Z represents C or N; X1, X2 and X3 are independent of each other and each represents a single bond, an optionally substituted C1-6 alkylene group, an optionally substituted C2-6 alkenylene group, an optionally substituted C2-6 alkynylene group, -NH-, -O-, -NHCO-, -CONH-, -SO0-2-, etc.; R1 and R2 are independent of each other and each represents a hydrogen atom or an optionally substituted C1-6 alkyl group, or R1 and R2 may be bound together such that CR2-ZR1 forms C=C; and R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group etc., or may be bound to any atom in A1 or A3 to form, together with the atom, an optionally substituted C5-8 hydrocarbon ring or an optionally substituted 5- to 8-membered heterocyclic ring.

  本发明提供了一种对 AMPA 受体和/或 kainate 受体具有良好抑制作用的新型化合物。也就是说，本发明提供了由下式代表的化合物、其盐或它们的水合物。 式中，A1、A2 和 A3 相互独立，各自代表 C3-8 环烷基、C3-8 环烯基、5-14 元非芳香杂环基、C6-14 芳香烃环基或 5-14 元芳香杂环基，其中每个基团都可以被取代；Q代表O、S或NH； Z代表C或N； X1、X2和X3彼此独立，各自代表单键、任选取代的C1-6亚烷基、任选取代的C2-6亚烯基、任选取代的C2-6亚炔基、-NH-、-O-、-NHCO-、-CONH-、-SO0-2-等。R1 和 R2 相互独立，各自代表氢原子或任选取代的 C1-6 烷基，或 R1 和 R2 可结合在一起，使 CR2-ZR1 形成 C=C；R3 代表氢原子或任选取代的 C1-6 烷基等、或可与 A1 或 A3 中的任一原子结合，与该原子一起形成任选取代的 C5-8 碳氢环或任选取代的 5-8 元杂环。
• Synthesis and pharmacological evaluation of 4,4a-dihydro-5H-[1]benzopyrano[4,3-c]pyridazin-3(2H)-ones bioisosters of antihypertensive and antithrombotic benzo[h]cinnolinones
  作者：G Cignarella、D Barlocco、MM Curzu、GA Pinna、P Cazzulani、M Cassin、B Lumachi

  DOI：10.1016/0223-5234(90)90194-8

  日期：1990.11

  A series of 4,4a-dihydro-5H-[1]benzopyrano[4,3-c]pyridazin-3-(2H)-ones (2a-h), have been prepared and evaluated for their pharmacological profile as antihypertensive and antithrombotic agents. Compounds 2 were ineffective in lowering the blood pressure of spontaneously hypertensive rats (SHR), only 2c (R1 = NHCOCH3) showing a short lasting action (< 2 h). Compounds 2c and 2b (R1 = NH2) were found to be very active as antithrombotic agents in mice, being more potent than acetylsalicylic acid (ASA) taken as reference drug. Moreover, many derivatives of this class protected rats from formation of ASA or phenylbutazone (PBZ) induced ulcers, the most active being 2f (R2 = OCH3) (ED50 = 12.2 mg/kg and 25.4 mg/kg po in ASA and PBZ models, respectively).
• Efficient Synthesis of Functionalized 1-oxo-1-phenyl-2-acetic Acids through Ru(II)-catalyzed Transfer Hydrogenation
  作者：Xiaowei Wang、Yunnan Yan、Binwei Gong、Xiaobo Tang、Qiu Li、Yanqiu Meng、H. Eric Xu、Wei Yi

  DOI：10.5012/bkcs.2013.34.10.3143

  日期：2013.10.20